Does particle radiation have superior radiobiological advantages for prostate cancer cells? A systematic review of in vitro studies

Author:

Du Tian-Qi,Liu Ruifeng,Zhang Qiuning,Luo Hongtao,Chen Yanliang,Tan Mingyu,Wang Qian,Wu Xun,Liu Zhiqiang,Sun Shilong,Yang Kehu,Tian Jinhui,Wang Xiaohu

Abstract

Abstract Background Charged particle beams from protons to carbon ions provide many significant physical benefits in radiation therapy. However, preclinical studies of charged particle therapy for prostate cancer are extremely limited. The aim of this study was to comprehensively investigate the biological effects of charged particles on prostate cancer from the perspective of in vitro studies. Methods We conducted a systematic review by searching EMBASE (OVID), Medline (OVID), and Web of Science databases to identify the publications assessing the radiobiological effects of charged particle irradiation on prostate cancer cells. The data of relative biological effectiveness (RBE), surviving fraction (SF), standard enhancement ratio (SER) and oxygen enhancement ratio (OER) were extracted. Results We found 12 studies met the eligible criteria. The relative biological effectiveness values of proton and carbon ion irradiation ranged from 0.94 to 1.52, and 1.67 to 3.7, respectively. Surviving fraction of 2 Gy were 0.17 ± 0.12, 0.55 ± 0.20 and 0.53 ± 0.16 in carbon ion, proton, and photon irradiation, respectively. PNKP inhibitor and gold nanoparticles were favorable sensitizing agents, while it was presented poorer performance in GANT61. The oxygen enhancement ratio values of photon and carbon ion irradiation were 2.32 ± 0.04, and 1.77 ± 0.13, respectively. Charged particle irradiation induced more G0-/G1- or G2-/M-phase arrest, more expression of γ-H2AX, more apoptosis, and lower motility and/or migration ability than photon irradiation. Conclusions Both carbon ion and proton irradiation have advantages over photon irradiation in radiobiological effects on prostate cancer cell lines. Carbon ion irradiation seems to have further advantages over proton irradiation. Graphical Abstract

Funder

Science and Technology Plan Project of Chengguan District of Lanzhou

the Talent Innovation and Venture Project of Lanzhou City

the Key R&D Program of Science and Technology Department of Gansu Province

the 2021 "Hundred Cities and Hundred Parks" Action Project of Lanzhou National High-tech Zone

National Key R&D Program of China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Reference120 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Corkum M, Loblaw A, Hasan Y, Chung HT, Tseng CL, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiother Oncol. 2021;156:160–5. https://doi.org/10.1016/j.radonc.2020.12.021.

3. Leite E, Ramos C, Ribeiro V, Salvajoli BP, Nahas WC, Salvajoli JV, et al. Hypofractionated radiation therapy to the prostate bed with intensity-modulated radiation therapy (IMRT): a phase 2 trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1263–70. https://doi.org/10.1016/j.ijrobp.2020.12.020.

4. Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, et al. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2020;142:62–71. https://doi.org/10.1016/j.radonc.2019.10.017.

5. Bai M, Gergelis KR, Sir M, Whitaker TJ, Routman DM, Stish BJ, et al. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Med. 2020;9(21):7925–34. https://doi.org/10.1002/cam4.3414.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3